Published in N Engl J Med on July 10, 1980
Mechanisms of drug-induced liver injury. AAPS J (2006) 1.65
Oxidative metabolism of halothane in the production of altered hepatocyte membrane antigens in acute halothane-induced hepatic necrosis. Gut (1981) 1.27
A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol (1984) 1.25
Liver membrane antibodies in alcoholic liver disease. II. Antibodies to ethanol-altered hepatocytes. J Clin Pathol (1983) 1.06
Anti-LSP antibodies in acute liver disease. Gut (1982) 1.05
Acute liver failure. Gut (1991) 0.98
Antibodies to alcohol altered liver cell determinants in patients with alcoholic liver disease. Gut (1984) 0.97
Anti-golgi complex autoantibodies in a patient with Sjögren syndrome and lymphoma. Clin Exp Immunol (1982) 0.96
Halothane-induced hepatitis: A forgotten issue in developing countries: Halothane-induced hepatitis. Hepat Mon (2011) 0.94
Immunological aspects of chronic active hepatitis. Clin Exp Immunol (1987) 0.94
Long-term ingestion of paracetamol and liver disease. J R Soc Med (1980) 0.93
Circulating immune complexes in patients with fulminant hepatic failure. Gut (1981) 0.93
Detection and partial characterization of circulating immune complexes in hydatid disease. J Clin Microbiol (1983) 0.91
Liver cell surface expression of the antigen reacting with liver-kidney microsomal antibody (LKM). Clin Exp Immunol (1984) 0.91
Characterization of a halothane-induced humoral immune response in rabbits. Clin Exp Immunol (1987) 0.90
The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur J Clin Pharmacol (2010) 0.89
Antibody mediated hepatocyte injury in methyl dopa induced hepatotoxicity. Gut (1985) 0.88
Tissue acylation by the chlorofluorocarbon substitute 2,2-dichloro-1,1,1-trifluoroethane. Proc Natl Acad Sci U S A (1991) 0.82
Chronology of halothane-induced antigen expression in halothane-exposed rabbits. Clin Exp Immunol (1988) 0.80
Immune mechanisms in tienilic acid associated hepatotoxicity. Gut (1989) 0.79
Halothane hepatitis in children. Br Med J (Clin Res Ed) (1987) 0.79
Cholestatic jaundice induced by flurazepam hydrochloride. Can Med Assoc J (1981) 0.76
Detection of autoantibodies directed against human hepatic endoplasmic reticulum in sera from patients with halothane-associated hepatitis. Br J Clin Pharmacol (1995) 0.76
Aetiology and pathophysiology of chronic liver disorders. Drugs (1990) 0.76
Halothane hepatitis in an animal model: time course of hepatic damage. Br J Exp Pathol (1987) 0.75
Generation of T cell responses targeting the reactive metabolite of halothane in mice. Toxicol Lett (2010) 0.75
Inhibition of bile secretion in the rat by serum ultrafiltrates and fractions from patients with fulminant hepatic failure. Br J Exp Pathol (1988) 0.75
Immunological aspects of liver disease. Gut (1991) 0.75
Drug metabolism and hepatotoxicity. Gut (1991) 0.75
The pathology of halothane hepatotoxicity in a guinea-pig model: a comparison with human halothane hepatitis. Br J Exp Pathol (1989) 0.75
Halothane hepatitis in children. Br Med J (Clin Res Ed) (1987) 0.75
Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. 5-7 April 1989, Bristol. Abstracts. Br J Clin Pharmacol (1989) 0.75
Shedding some light on the halothane controversy. Anesth Prog (1980) 0.75
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
An immunoglobulin heavy chain variable region gene is generated from three segments of DNA: VH, D and JH. Cell (1980) 10.35
Two mRNAs can be produced from a single immunoglobulin mu gene by alternative RNA processing pathways. Cell (1980) 9.86
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens (2004) 8.32
Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43
Cost analysis of early discharge after hip fracture. BMJ (1993) 6.64
Deaths from low dose paracetamol poisoning. BMJ (1998) 6.63
Anti-tuberculous therapy and acute liver failure. Lancet (1995) 6.27
Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med (2000) 6.07
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
Elective ventilation of potential organ donors. BMJ (1995) 5.50
Mechanisms of fear extinction. Mol Psychiatry (2006) 5.44
Acute liver failure: redefining the syndromes. Lancet (1993) 4.99
Vulnerability genes or plasticity genes? Mol Psychiatry (2009) 4.96
Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature (1998) 4.89
Antibody diversity: somatic hypermutation of rearranged VH genes. Cell (1981) 4.65
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57
Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet (1971) 4.49
Geobacter sulfurreducens sp. nov., a hydrogen- and acetate-oxidizing dissimilatory metal-reducing microorganism. Appl Environ Microbiol (1994) 4.44
Liver transplantation in man. I. Observations on technique and organization in five cases. Br Med J (1968) 4.38
Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet (1990) 4.27
Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed) (1986) 4.16
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Daily variation of particulate air pollution and poor cardiac autonomic control in the elderly. Environ Health Perspect (1999) 4.07
A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology (1994) 4.01
Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet (1972) 3.90
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Activation of the left amygdala to a cognitive representation of fear. Nat Neurosci (2001) 3.71
Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet (1974) 3.61
A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature (1992) 3.59
Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci (1992) 3.40
Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess (2007) 3.40
Structured patient education: the diabetes X-PERT Programme makes a difference. Diabet Med (2006) 3.36
A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet (1998) 3.33
Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med (1978) 3.28
Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med (1992) 3.24
HCV-associated liver cancer without cirrhosis. Lancet (1995) 3.23
NHLBI Family Heart Study: objectives and design. Am J Epidemiol (1996) 3.21
High molecular gas fractions in normal massive star-forming galaxies in the young Universe. Nature (2010) 3.18
Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature (1974) 3.17
Definition of subchromosomal intervals around the myotonic dystrophy gene region at 19q. Genomics (1989) 3.16
Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis. Lancet (1976) 3.16
Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol (1977) 3.13
Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut (1999) 3.10
Improved survival after orthotopic liver grafting. Br Med J (Clin Res Ed) (1981) 3.09
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
Mutations that alter the ability of the Escherichia coli cyclic AMP receptor protein to activate transcription. Nucleic Acids Res (1990) 3.08
Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet (1998) 3.06
Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04
Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet (1973) 2.98
Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet (1979) 2.98
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia (2009) 2.98
Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ (1991) 2.94
More donor organs for transplantation. Elective ventilation proposals. J R Coll Physicians Lond (1993) 2.91
Double dissociation between the involvement of the bed nucleus of the stria terminalis and the central nucleus of the amygdala in startle increases produced by conditioned versus unconditioned fear. J Neurosci (1997) 2.90
Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med (1973) 2.88
Determinants of participation in state-of-the-art cancer prevention, early detection/screening, and treatment trials among African-Americans. Cancer Nurs (1993) 2.87
Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J (1971) 2.86
The arthropathy of idiopathic haemochromatosis. Q J Med (1968) 2.85
Hepatitis B virus infection in medical and health care personnel. Br Med J (Clin Res Ed) (1982) 2.85
Liver transplantation after paracetamol overdose. BMJ (1991) 2.81
The NHS as a theological institution. The ideal remains strong, but the practice too has to measure up. BMJ (2000) 2.81
New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol (1997) 2.78
Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet (1989) 2.76
A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med (1991) 2.75
Liver in Felty's syndrome. Br Med J (1970) 2.75
A primary acoustic startle circuit: lesion and stimulation studies. J Neurosci (1982) 2.73
Trends in sexual behaviour among London homosexual men 1998-2003: implications for HIV prevention and sexual health promotion. Sex Transm Infect (2004) 2.72
Hepatic damage and death from overdose of paracetamol. Lancet (1973) 2.70
Extrahepatic biliary atresia versus neonatal hepatitis. Review of 137 prospectively investigated infants. Arch Dis Child (1976) 2.67
Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67
Offering choice of treatment to patients with cancers. A review based on a symposium held at the 10th annual conference of The British Psychosocial Oncology Group, December 1993. Eur J Cancer (1995) 2.66
A test of the nature of cosmic acceleration using galaxy redshift distortions. Nature (2008) 2.65
Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med (1991) 2.65
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology (1988) 2.60
Treatment of hepatic encephalopathy. N Engl J Med (1997) 2.60
Fear and anxiety: animal models and human cognitive psychophysiology. J Affect Disord (2000) 2.58
Liver transplantation. Curr Probl Surg (1979) 2.57
A radiation hybrid map of the rat genome containing 5,255 markers. Nat Genet (1999) 2.54
Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysis. Lancet (1977) 2.53
Mouse Cmu heavy chain immunoglobulin gene segment contains three intervening sequences separating domains. Nature (1980) 2.52
Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut (1998) 2.51
Orthotopic liver transplantation: the first 60 patients. Br Med J (1977) 2.50